Skip to content

SIGNPATH PHARMA, INC.: 10-Q filed 2014-08-18

What SIGNPATH PHARMA, INC. reported in its quarterly report filed 2014-08-18 (fiscal Q2 2014): 20 published measures, 60 facts as tagged in accession 0001096906-14-001185.

This filing

Form
10-Q (quarterly report)
Filed
2014-08-18
Fiscal period
fiscal Q2 2014
Accession
0001096906-14-001185 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All SIGNPATH PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-06-301,640,573USD
At 2013-12-311,241,397USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-06-301,259,799USD
At 2013-12-31819,765USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-958,713USD91
2014-01-01 to 2014-06-30-1,156,889USD181
2006-05-15 to 2014-06-30-11,825,297USD2969
2013-04-01 to 2013-06-30-413,942USD91
2013-01-01 to 2013-06-30-1,182,693USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2014-01-01 to 2014-06-30-973,360USD181
2006-05-15 to 2014-06-30-6,920,171USD2969
2013-01-01 to 2013-06-30-790,504USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2006-05-15 to 2014-06-305,390USD2969

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-01-01 to 2014-06-301,372,536USD181
2006-05-15 to 2014-06-308,566,134USD2969
2013-01-01 to 2013-06-302,125,849USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2006-05-15 to 2014-06-30-5,390USD2969

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-958,913USD91
2014-01-01 to 2014-06-30-1,157,285USD181
2006-05-15 to 2014-06-30-10,855,262USD2969
2013-04-01 to 2013-06-30-346,834USD91
2013-01-01 to 2013-06-30-1,178,933USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-06-301,640,573USD
At 2013-12-311,241,397USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-06-30380,774USD
At 2013-12-31421,632USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-04-01 to 2014-06-30958,913USD91
2014-01-01 to 2014-06-301,157,285USD181
2006-05-15 to 2014-06-3010,855,262USD2969
2013-04-01 to 2013-06-30346,834USD91
2013-01-01 to 2013-06-301,178,933USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-04-01 to 2014-06-30616,750USD91
2014-01-01 to 2014-06-30746,538USD181
2006-05-15 to 2014-06-305,043,971USD2969
2013-04-01 to 2013-06-30187,657USD91
2013-01-01 to 2013-06-30306,068USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-06-3012,917,500shares
At 2013-12-3112,877,500shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-06-3011,402,977USD
At 2013-12-3110,120,454USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-06-305,390USD
At 2013-12-315,390USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-958,713USD91
2014-01-01 to 2014-06-30-1,156,889USD181
2006-05-15 to 2014-06-30-11,825,297USD2969
2013-04-01 to 2013-06-30-413,942USD91
2013-01-01 to 2013-06-30-1,182,693USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-306,700USD91
2014-01-01 to 2014-06-3014,460USD181
2006-05-15 to 2014-06-301,318,056USD2969
2013-04-01 to 2013-06-308,679USD91
2013-01-01 to 2013-06-3013,821USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2006-05-15 to 2014-06-30-5,390USD2969
2013-01-01 to 2013-06-30-144USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2014-04-01 to 2014-06-30200USD91
2014-01-01 to 2014-06-30397USD181
2006-05-15 to 2014-06-30-970,034USD2969
2013-04-01 to 2013-06-30-67,108USD91
2013-01-01 to 2013-06-30-3,760USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2006-05-15 to 2014-06-3010,000USD2969

Inspect the source

Entity
SIGNPATH PHARMA, INC. / CIK 0001455694
Captured
SEC response SHA-256
571c6c49907c5089f4ba741647c70ec6289859c58fc4769a714d176dd34fe3b6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001455694.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))